Biotech
Aug. 11, 2011
Stephen B. Thau
Thau's corporate practice includes financing and partnership negotiations for biotechnology and medical device companies.
"It's been a mix recently of some very good, encouraging early-stage companies that have secured lots of financing," Thau said.
He represented Novato-based Ultragenyx Pharmaceutical Inc. when it raised $45 million from venture capital investors in June to fund drug development for rare diseases and clini...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In